Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M

CYTOKINETICS INC

2025-FY EPS reported -$6.54 revenue$88,039,000

Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).
Revenue Q4 $17.8M (up 5% YoY); full year $88.0M (up 376% YoY) from Bayer tech transfer $52.4M and Sanofi milestones $15.0M.
Cash $1.22B at Dec 31 2025; Q4 cash burn ~$134M excluding $100M loan draw from Royalty Pharma.
MYQORZO (aficamten) approved for oHCM in US (Dec 2025), China, EU; US launch underway Jan 2026; ACACIA-HCM topline expected Q2 2026.
FY 2026 GAAP combined R&D+SG&A guidance $830-870M; non-cash stock comp $130-120M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.